Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7539718 | 1.00 | BACE1 (0.51) | BACE1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2962853 | 0.90 | BACE1 (0.39) | BACE1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8188262 | 0.90 | BACE1 (0.39) | BACE1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7540732 | 0.89 | BACE1 (0.50) | BACE1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12173537 | 0.89 | BACE1 (0.50) | BACE1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14105205 | 0.89 | BACE1 (0.52) | BACE1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12191465 | 0.88 | BACE1 (0.49) | BACE1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8210342 | 0.88 | BACE1 (0.49) | BACE1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7601017 | 0.88 | BACE1 (0.49) | BACE1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13054398 | 0.88 | BACE1 (0.49) | BACE1CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242112-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2012-08-14 | — | — | US | disclosed |
| US-20110218194-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | Schering Corporation & Pharmacopeia Drug Discovery Inc. (US) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218194-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | BACE1 8/4885CYP3A4 853/4885CYP2D6 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.